Salarius Pharmaceuticals Says It Became Aware That Certain Financial Market Data Platforms Published That Co. Had Been Delisted From Nasdaq; Information That Co. Had Been Delisted From Nasdaq Is Inaccurate

On November 17, 2025, Salarius Pharmaceuticals, Inc. (the "Company") became aware that certain financial market data platforms, including Yahoo Finance and CapIQ, published information stating that the Company had been delisted from the Nasdaq Capital Market effective November 13, 2025. This information is inaccurate. The Company's common stock continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol "SLRX". The Company has contacted these platforms to correct this inaccurate information.

As previously disclosed, on September 4, 2025, the Company received a letter from the Nasdaq Hearings Panel (the "Hearings Panel") of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance with the minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). Subsequently, on October 10, 2025, the Company received a letter from the Hearings Panel notifying the Company that it had regained compliance with Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard"). On November 13, 2025, the Company announced that it had completed its strategic merger transaction with Decoy Therapeutics, Inc. Following consummation of the merger, the Company continues to be listed and traded on the Nasdaq Capital Market under the ticker symbol "SLRX." The Company has not received any notification from Nasdaq indicating that it is not compliant with the continued listing requirements of the Nasdaq Capital Market.

The information in this Item 7.01 is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such filing.